Clinical Trial Diversity—Will We Know It When We See It?-Reference-Cited by-同舟云学术

Clinical Trial Diversity—Will We Know It When We See It?

Published:2023-06-01 Issue:6 Volume:9 Page:765
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Varma Tanvee¹,Gross Cary P.¹²,Miller Jennifer E.¹³

Affiliation:

1. Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

2. National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut

3. Yale Equity Research and Innovation Center (ERIC), New Haven, Connecticut

Abstract

This Editorial discusses the existing policy efforts in the US for ensuring adequate racial and ethnic diversity in clinical trials, identifies barriers to consistency and acceptable representation, and suggests measures to address them.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2803091/jamaoncology_varma_2023_ed_230006_1686773077.55536.pdf

Reference9 articles.

1. Race/ethnicity reporting and representation in US clinical trials: a cohort study.;Turner;Lancet Reg Health Am,2022

2. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study

3. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.;Poon;J Womens Health (Larchmt),2013

4. Ethical considerations in international clinical trial site selection.;Miller;BMJ Glob Health,2022

5. Addressing racial, ethnic, and age disparities in cancer clinical trial enrollment: time to stop tinkering around the edges.;Gaddy;JAMA Oncol,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inclusivity of patients in early phase breast cancer clinical trials;Journal of Cancer Policy;2024-09

2. Are community oncology practices with or without clinical research programs different? A comparison of patient and practice characteristics;JNCI Cancer Spectrum;2024-07-01

3. Incorporating Real-World Clinico-Genomic Insights to Inform Diversity Enrollment Targets in Oncology Trials;2024-04-19

4. Reporting of Demographics & Subgroup Analyses in Premarketing Studies of FDA Approved High-Risk Cardiovascular Devices, 2014–2022;Medical Devices: Evidence and Research;2024-04

5. Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia;JNCI: Journal of the National Cancer Institute;2024-03-22